We enrolled 382 college-age women in a cross-sectional survey to investigate the relationship between use of over-thecounter (OTC) azole-based antifungal drugs and vaginal colonization by drug-resistant Candida. This study showed no correlation ( ) between previous OTC exposure P p .506 and colonization of drug-resistant Candida in vaginal flora. However, a small number of resistant Candida species isolates were obtained from women with a history of multiple exposures to OTC antifungals; given the widespread use of these products, this may be an emerging concern.
from C. albicans to more intrinsically azole-resistant species, as has been described for immunosuppressed women [4, 7] .
In the 1990s, there was a significant increase in the prevalence of drug-resistant fungal infections due to Candida species in patients hospitalized for mucosal or systemic diseases [8] [9] [10] . The widespread application of fluconazole or related azole antifungals is postulated to promote selection of resistant subpopulations by shifting colonization to more naturally resistant species, such as Candida krusei or Candida glabrata [11] [12] [13] . Alternatively, azole-resistant subspecies have arisen in vivo and in vitro that show changes in the target enzyme lanosterol 14-a-demethylase, in expression of multidrug efflux pumps, or in both [14] [15] [16] .
Numerous effective topical vaginal antimycotic agents are available that provide high cure rates with favorable therapeutic indexes. Given the growing correlation between azole antifungal exposure and emergence of drug-resistant Candida species, there is a concern that this problem may be exacerbated in healthy women by use of over-the-counter (OTC) products, which became available in the early to mid-1990s for self-treatment of vaginitis [5, 6] . Most notably, because many of the OTC drugs are azole based, it is likely that frequent or prolonged use of these products has the potential to select for widespread drug resistance. In fact, cross-resistance between OTC drugs (miconazole, clotrimazole, and tioconazole) and fluconazole has been observed in clinical isolates of C. glabrata and C. albicans [17, 18] .
To better address this concern, a multicenter, cross-sectional study was initiated at 2 major university health services centers to explore the causal relationship between OTC antifungal use by healthy college-age women and vaginal colonization with fluconazole-resistant Candida species Materials and methods. The multicenter, cross-sectional study was conducted at Columbia University Health and Related Services and Cornell University Health Services from March through July 1999 in New York. All women undergraduate and graduate students who were at least 18 years old and had a pelvic examination scheduled were asked to participate in the study. Of the subjects approached in clinic, 382 women agreed to have administered to them the terms of informed consent and allowed vaginal swabs to be obtained. Enrolled patients were given a brief health history questionnaire, and samples were obtained for culture on the same day.
The samples were collected by clinicians on site from the patient's vaginal pool by use of a sterile cotton swab. Swabs were directly inoculated onto a sterile slant containing Sa- Fisher's exact test and x 2 tests were used to compare proportional differences for given categorical and continuous variables between subjects with Candida-positive cultures and those with Candida-negative cultures. Binomial and Poisson 95% confidence intervals were calculated for prevalence of Candida and drug-resistant forms, as appropriate. Analysis was carried out by SAS, version 7 (SAS).
Results. A total of 382 subjects participated in the study, 272 from Columbia and 110 from Cornell; they ranged in age from 18 to 54 years. The mean for the participants age ‫ע‬ SD was years for students from Columbia and 27 ‫ע‬ 5.2 24 ‫ע‬ 5.1 years for students from Cornell. Students enrolled at Columbia were significantly older and had been in school longer (P ! ) than Cornell students. The distribution of other charac-.0001 teristics, such as ethnic makeup, previous OTC azole antifungal use, number of vaginal infections in the past 5 years, and presence in the clinic for routine examination, was not distinguishable between centers. The proportion of patients who were symptomatic for vaginitis, the number who had previously used fluconazole, and the percentage of patients who harbored yeast also were not significantly different between the 2 sites.
Approximately 26.4% of all subjects (101 of 382) were identified as harboring yeast in the vaginal flora ( ) between isolation of yeast in samples P p .0579 from women with a history of vaginitis episodes. However, among patients with recurring infections (defined as 3 or more per year), there was a significant correlation ( ) with P p .0388 yeast colonization.
Yeast isolates (C. albicans) exhibiting resistance (MIC, 164 mg/mL) to fluconazole were recovered from 2 of the 382 women from whom samples were taken. Both students were 30 years old and had histories of vaginitis episodes, with 1 reporting recurring infections within the past year. Neither of the 2 carriers reported previous exposure to fluconazole; however, both patients previously had used azole-based OTC antifungal medication to treat an episode of vaginitis. One patient was symptomatic for vaginitis, and the other was at the clinic for a routine pelvic examination. The presence of 2 fluconazoleresistant isolates indicates a prevalence of 1.98% (95% Poisson CI, 0.24%-7.15%) among the total yeast isolated (101 isolates). From the total sample, 1 woman was found to be colonized with a C. albicans isolate that revealed dose-dependent susceptibility to fluconazole (MIC, 16-32 mg/mL). This patient, who was asymptomatic for vaginitis at the time of collection, had frequent yeast infections and had previous exposure to azole-based OTC antifungals. But the patient did not report a history of fluconazole use.
Among the 5 C. glabrata isolates recovered from the total sample, only 1 expressed intermediate dose-dependent fluconazole resistance. The carrier was an asymptomatic 26-year-old woman who reported that she had never experienced an episode of yeast infection or exposure to OTC azole medication or fluconazole. The isolate from this woman showed evidence of resistance to amphotericin B (MIC, 11 mg/mL).
Fifty-eight percent (220 of 382) of the women in this study reported use of OTC medication to treat episodes of vaginitis. Of those 220 women, 28.6% (63 women) were colonized with yeast. There was no statistically significant association between the use of OTC medication for vaginal yeast infections and occurrence of fluconazole resistance ( ) in the study P p .6403 population. The association between prior OTC azole antifungal use and fluconazole resistance when the analysis was controlled for previous exposure to fluconazole was not significant ( ). Interestingly, all 3 patients harboring C. albicans P p .6291 isolates with decreased susceptibility to fluconazole (2 resistant isolates and 1 isolate with dose-dependent susceptibility) reported previous OTC azole antifungal use.
Discussion. In this study, we demonstrate that previous exposure to OTC azole antifungal drugs is not associated with widespread colonization of drug-resistant Candida species in the vaginal flora of largely healthy college-age women. In contrast to oropharyngeal candidiasis in patients with AIDS, azole resistance has only been reported in 1 case of vaginitis caused by C. albicans [20] . In vitro resistance remains rare among isolates from women with vaginitis due to C. albicans, even among isolates from HIV-positive women, in whom there is a tendency for such infections to occur in the oral cavity. The same is true of patients with recurrent vulvovaginal candidiasis in which vaginal isolates remain susceptible to azole-based antifungal drugs and do not show increased resistance to any drug despite long-term exposure to azoles [21] . The results of this study support this finding (table 1) .
The widespread use of azoles has led to an increase in the prevalence of fluconazole-resistant non-C. albicans species, especially C. glabrata [4, 7, 8, 18, 22, 23] . Of the 5 C. glabrata isolates recovered, only 1 expressed intermediate dose-dependent (MIC, 132 mg/mL) fluconazole resistance. The source was an asymptomatic 26-year-old woman who had no history of either a yeast infection or exposure to azole antifungals. It is noteworthy that this isolate was cross-resistant to amphotericin B (MIC, 11 mg/mL). Although such findings are unusual, similar findings have been reported for fluconazole-resistant C. albicans isolates recovered from both HIV-positive and healthy people who had never taken fluconazole or other azoles [24, 25] .
The presence of asymptomatic women colonized with azoleresistant strains has important implications for therapeutic management of future vaginitis episodes in these women. Perhaps of more concern is the possibility that a primary drugresistant colonizing strain could predominate at later time if the women become immunosuppressed. Furthermore, the spread of these primary drug-resistant colonizers by sexual transmission is a distinct possibility [26] . If candidiasis is caused by the host's original commensal strain or strains, knowledge of the yeast microflora of high-risk patients before the manifestation of candidiasis (e.g., susceptibility to different antifungal drugs) could lead to improved strategies for prophylaxis and treatment [23] .
Another concern is the transmission of drug-resistant commensal colonizing strains to family members. Muller et al. [27] reported that transmission of azole-resistant strains from symptomatic HIV-infected patients with oropharyngeal candidiasis to asymptomatic family members is possible and may represent a previously underappreciated risk for families that include members infected with HIV. The acquisition of an azole-resistant strain of C. albicans by an asymptomatic patient has important clinical implications, especially in high-risk populations where presentation of oropharyngeal candidiasis may result in therapy refractory to azoles.
Yeast were isolated from 26.4% (101) of the women (table 1) in this study, which is consistent with previous point-prevalence studies, in which asymptomatic vaginal colonization with Candida was observed in 10%-55% of healthy adult women [28] . Despite exposure to azole antifungals of 150% among all patients, C. albicans was the predominant species found, accounting for 92.1% (93) of all isolates. The selection of non-C. albicans species, especially C. glabrata, in HIV-positive women receiving fluconazole therapy is well established, although C. albicans is still the predominant pathogen, at 185% of all isolates from HIV-seronegative women [2] . Our study has a number of limitations. First, detailed clinical chart reviews were not available to us, which might limit the associations we can suggest between clinical risk factors and drug-resistant yeast colonization. In addition, there may have been an element of recall bias regarding previous exposure to azole-based OTC. However, in either instance, we would expect our estimates to point away from an association between previous OTC usage and drug-resistant colonization. We believe neither to be the case in this study. The importance of the lack of statistical association seen in our study is limited by the small sample size; a true lack of association may not be indicated by our results. However, this study provides a baseline against which the general prevalence of colonization may be assessed and the relationship between previous OTC usage and resistance may be determined. More extensive populationbased studies will be required to fully address this question.
Finally, the results in this study suggest that previous exposure to OTC azole-based antifungal drugs used to treat vaginal yeast infections is not a significant risk factor for evolution of clinical drug resistance in strains colonizing the genitourinary tract. However, it is noteworthy that 4 isolates (of 101) were shown either to be resistant to fluconazole (2 isolates) or to have intermediate dose-dependent susceptibility (2 isolates). Three of these isolates originated in women with a history of multiple OTC antifungal exposures. This observation, although anecdotal, is troubling, given that millions of women annually use OTC antifungal products (a market of almost $300 million), and these commensal strains may predominate if the women later become immunosuppressed.
